Keywords: spectrum, starts, ph, ii, spi-153, cancer, trial

Spectrum starts Ph II SPI-153 cancer trial

Article | 18 April 2005

Print This

California, USA-based Spectrum Pharmaceuticals has launched a Phase II clinical study to evaluate the safety and efficacy of its SPI-153 ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in